All In Biotech

Drug Trial Radar · NCT03971370

Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .

Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine in Chinese Healthy People Aged 10-60 Years.: A Randomized, Blinded, Phase III Clinical Trial.

Last checked: Nov 20, 2026Latest source record: Jun 3, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,800

Actual

Start

Sep 10, 2017

Primary completion

Sep 29, 2018

Study completion Feb 22, 2019

Sponsor

Sponsor type
Research network
First posted
Jun 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 10 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals. The WHO clearly states that human diploid cell rabies vaccine is the "gold standard" rabies vaccine, because of no carcinogenicity and any foreign animal impurity or neurotoxicity factor. China does not approve the import of foreign HDCV and has insufficiency domestic HDCV, so this clinic trial was to assess the immunogenicity and safety of HDCV in healthy population for the large-scale developing of a lyophilized and purified HDCV.

Conditions

  • Adverse Effect and Immunogenicity of Vaccine

Interventions

  • Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)Biological

    Essen post-exposure immunization schedule at day 0,3,7,14,28.

  • Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd)Biological

    Zagreb post-exposure immunization schedule at day 0,7,21.

  • Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)Biological

    Essen post-exposure immunization schedule at day 0,3,7,14,28.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate immunogenicity after the first doseTime frame: 14 days following the first dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jiangsu Provincial Center for Diseases Control and Prevention

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.